Amgen

2500 articles about Amgen

• TEZSPIRE® approved for self-administration in the US with a new pre-filled pen

  2/2/2023

  AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.

• TEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN

  2/2/2023

  Amgen (NASDAQ:AMGN) and AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE® (tezepelumab-ekko) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.

• Amgen Posts Full Transcript and Audio Replay of Fourth Quarter and Full Year 2022 Earnings Webcast

  2/1/2023

  Amgen posted the full transcript and audio replay of the company's 2022 fourth quarter and full year financial results webcast from earlier.

• AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES

  1/31/2023

  Amgen (NASDAQ:AMGN) today announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira ®*  (adalimumab), is now available in the United States.

• AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS

  1/31/2023

  Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year 2022 versus comparable periods in 2021.

• 

  Amgen Downsizes by 300 Amid Industry Constriction

  1/30/2023

  Amgen is implementing organizational changes including laying off approximately 300 team members, confirmed Monday.
• 

  Market Skeptical Following Sen. Warren's Antitrust Allegations

  1/27/2023

  Sen. Elizabeth Warren (D-MA) voiced concerns to the FTC regarding the prospective acquisitions of Horizon Pharmaceuticals and Opiant Pharmaceuticals by Amgen and Indivior.

• AMGEN ANNOUNCES WEBCAST OF 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

  1/26/2023

  Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, Jan. 31, 2023, after the close of the U.S. financial markets.

• The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgen’s Commitment of $8 Million

  1/19/2023

  The Robert A. Winn Diversity in Clinical Trials Award Program established by the Bristol Myers Squibb Foundation announced that Amgen, a global biotechnology company, has committed to contribute $8 million over the next four years.

• EVOQ Therapeutics and Amgen Expanding Collaboration

  1/18/2023

  EVOQ Therapeutics today announced the advancement of their ongoing license and collaboration agreement with Amgen for the discovery and development of novel therapeutics including the receipt of a milestone payment and expansion of the scope of collaboration to include a total of three indications in autoimmune disorders.

• 

  Amgen Boasts Lucrative Acquisitions, Drug Updates, Burgeoning Biosimilars at JPM

  1/10/2023

  In a presentation led by Robert J. Bradway, Amgen chairman and chief executive officer, the company covered recent acquisitions, Repatha and Lumakras updates, biosimilars and its broader financial outlook.
• 

  Amgen Makes Early $2B Play to Boost ADC Portfolio

  1/6/2023

  In another early high-value deal, Amgen inked a licensing agreement with Synaffix for the development of next-generation antibody-drug conjugates. 

• Amgen and Biolabs LA at the Lundquist Institute Announce Nammi Therapeutics to Receive the Third Amgen Golden Ticket

  1/6/2023

  Amgen and BioLabs LA at The Lundquist Institute announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticket in Southern California.

• 

  Reanalysis of Key Trial Flags Fresh Safety Concerns for Amgen’s Repatha (Updated)

  1/4/2023

  Amgen’s Repatha may cause cardiac harm, according to a reassessment of the biologic’s late-stage trial data.

• AMGEN TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

  1/4/2023

  Amgen (NASDAQ:AMGN) will present at the 2023 J.P. Morgan Healthcare Conference at 6:45 p.m. ET on Monday, January 9, 2023. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference.

• LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates

  12/23/2022

  LCB Grants Amgen Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates Combining Targets Selected by Amgen with LCB’s Proprietary ADC Platform.

• Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen

  12/20/2022

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced a $25M milestone payment from Amgen (NASDAQ: AMGN).

• 

  Mirati Challenges Amgen in KRAS Space with FDA Accelerated Approval

  12/13/2022

  Mirati gets the green light from the FDA for its KRAS G12C-mutated lung cancer medication.

• BLINCYTO® (BLINATUMOMAB) ADDED TO CONSOLIDATION CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN ADULT PATIENTS WITH MEASURABLE RESIDUAL DISEASE-NEGATIVE B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

  12/13/2022

  Amgen (NASDAQ: AMGN) today announced the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present results from the E1910 randomized Phase 3 trial.

• 

  Amgen to Buy Horizon in Biotech’s Biggest Deal of 2022

  12/12/2022

  Amgen confirmed Monday it will acquire rare disease giant Horizon Therapeutics for $26.4 billion.